Publications by authors named "Ahmad Kh Ibrahimi"
Article Synopsis
- Adult medulloblastoma is uncommon, and treatment insights are mostly drawn from studies of pediatric cases; this study analyzed adult cases treated at King Hussein Cancer Center to understand clinical features and outcomes.
- The study included 53 patients aged 18 and older, with comprehensive assessments of disease characteristics and treatment responses over a median follow-up of 70 months, noting that 37.7% of patients died during this period.
- The findings highlighted significant correlations between patient outcomes and factors such as the extent of surgery and risk status, while molecular subgrouping did not predict survival outcomes, indicating a need for more aggressive treatment in high-risk patients.
Introduction: Most pediatric low-grade-gliomas (LGG) and some high-grade-gliomas (HGG) have alterations in the RAS/MAPK pathway. Promising high tumor response rates were achieved using BRAF/MEK inhibitors, however data on their use in low-middle-income-countries (LMICs) are limited.
Methods: We retrospectively reviewed our Jordanian experience of using compassionate BRAF/MEK inhibitors in treating children with gliomas.
Background: Breast cancer remains a leading cause of cancer-related mortality and morbidity worldwide. Ocular and periocular metastasis present as a rare but clinically significant manifestation. This study aims to explore demographics and clinical aspects of ocular and periocular metastasis in breast cancer patients.
View Article and Find Full Text PDFArticle Synopsis
- Advances in molecular diagnostics have led to better treatment options for pediatric CNS tumors, but testing access is limited in low- and middle-income countries (LMICs), necessitating further analysis of their effectiveness.
- A review of next-generation sequencing (NGS) testing at KHCC in Jordan revealed that 14% of discussed patients were included, with a median age of 9.5 years and various tumor types primarily being low-grade and high-grade gliomas.
- NGS testing identified targetable genetic alterations in 59% of cases, influencing treatment decisions, with processing averages around 23.5 days and costing approximately $1,000 per sample.
Background: The number of cancer survivors and survivorship are increasing. Health-related quality of life (HRQOL) has not been widely studied in low-and-middle-income countries (LMICs). The aim of this study is to explore HRQOL of childhood brain tumor survivors and its determinants in Jordan.
View Article and Find Full Text PDFArticle Synopsis
- - Brain metastasis from colorectal cancer is rare and typically has a poor prognosis, making treatment challenging.
- - The primary treatment for brain metastasis is radiotherapy, while systemic options include targeted therapies and chemotherapy, but their effectiveness on brain metastasis is not fully proven.
- - A case is reported where a patient with brain metastasis from colorectal cancer showed significant improvement after receiving a combination of capecitabine, oxaliplatin, and cetuximab.